💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Paroxetine

CHEMBL490 Phase 4 Onaylandı Small molecule
Half-Life
21 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
329.4 g/mol
LogP
3.5
Phase
4

This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

Moleküler Ağırlık

329,3730 g/mol

LogP

3,50

TPSA

39,70 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Hepatitis C Prostate Cancer Colorectal Cancer

İlaç Sınıfları

N — N - Nervous System

Etki Mekanizması

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

Pharmacokinetics (PK)

Half-Life 21 hours

Pharmacodynamics (PD)

Mekanizma

Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H20FNO3

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
4

                    

                    
                    
                    

                        
Ağır Atomlar

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
This SSRI antidepressant treats depression, anxiety disorders, obsessive-compulsive disorder, and other mental health conditions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Potent selective serotonin reuptake inhibitor with additional muscarinic and NE reuptake inhibition.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Paroxetine: Half-life: 21 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Paroxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL490.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 43815.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.